SG-210

SG-210 (SPR 210) is an orally active and selective aldose reductase (AR) inhibitor. SG-210 has IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. SG-210 can inhibit sorbitol accumulation and ameliorate diabetic neuropathy and retinopathy in Streptozotocin (HY-13753) -induced diabetic rats. SG-210 can be used in the research of diseases such as diabetes-related complications[1].

Product Specifications

CAS Number

[143162-65-6]

Product Name Alternative

SPR 210

UNSPSC

12352005

Target

Aldose Reductase

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease

Smiles

O=C1N(CC2=NC3=C(S2)C(F)=CC(F)=C3F)C4=CC=CC=C4SC1CC(O)=O

Molecular Formula

C18H11F3N2O3S2

Molecular Weight

424.42

References & Citations

[1]Matsui T, et al. Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn J Pharmacol. 1994 Feb;64 (2) :115-24.